Newsroom
CV6 Therapeutics Appoints Dr. Chris Takimoto to Board of Directors
CV6 Therapeutics today announced the appointment of veteran oncology drug developer Dr. Chris Takimoto to its Board of Directors as the company advances its lead program, CV6-168, through Phase 1a clinical development.
CV6 Therapeutics Contributes to Discussions on the Future of Oncology Innovation Across Ireland
Dr. Robert D. Ladner, CEO and Founder of CV6 Therapeutics, was invited to join leading voices from industry, healthcare, academia, and government at two major oncology innovation events in Dublin to discuss opportunities to accelerate cancer research, clinical development, and...
CV6 Therapeutics Joins QUBIS “Spin Out to Stand Out” Event at Queen’s University Belfast
CV6 Therapeutics was proud to participate in “Spin Out to Stand Out,” a recent alumni and innovation event hosted by Queen's University Belfast and QUBIS on Wednesday, 29 April 2026, highlighting the strength of Northern Ireland’s growing entrepreneurial ecosystem.
CV6 Announces Initiation of Patient Dosing in CV6-168 Phase 1a Clinical Trial
CV6 Therapeutics (NI) Ltd. (“CV6”) today announced the successful dosing of the second patient in its Phase 1a study evaluating CV6-168 + infusional 5-fluorouracil (5-FU) in cancer patients.
CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting
CV6 Therapeutics (‘CV6’) will be presenting details of their ongoing CV6-168 Phase 1a clinical trial at the 2024 ASCO Annual Meeting to be held at McCormick Pace in Chicago, USA on May 31st to June 4th.
CV6 Therapeutics to Attend JP Morgan Week
CV6 Therapeutics Inc., CEO and Founder, Dr Robert Ladner will be attending JP Morgan Week, to be held on the 8th-12th January at the Marriott Marquis in San Francisco, California, USA.